Praxis pauses vormatrigine study after trial misses primary endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Praxis Precision Medicines Provides Vormatrigine Program Update
June 1, 2026 4:15 PM EDTPOWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure
Secondary measure, the 50% response rate, was met and seizure reduction during the second half of the study on higher dose (30 mg) was more pronounced
Vormatrigine was generally well-tolerated; adverse event-related discontinuations were less than 10%
Approximately 90% of patients from the vormatrigine arm transitioned to and remain in the open label extension (OLE) study
Praxis is pausing enrollment in the POWER2 study to reassess the vormatrigine program and... More
